Latest News and Events
Filter by
Selections
June 18, 2018
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreJune 8, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreMay 30, 2018
Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
Read MoreMay 21, 2018
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
Read MoreMay 14, 2018
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
Read MoreMay 11, 2018